Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Targeted agents in the treatment of advanced NSCLC

ECCO 15 - ESMO 34

20 - 24 Sep 2009

Published: 2 Nov 2009

Views: 13280

Rating:

Save

Prof Johan Vansteenkiste - Leuven University Hospital, Belgium

Targeted agents in the treatment of advanced NSCLC. New data on Zactima. Zactima in combination with standard chemotherapy. Immunotherapy and the MAGE-A3 vaccine. Speaking at ECCO 15 - ESMO 34, Berlin, 2009.

Related Videos

The case for global gender-neutral HPV vaccination

Peter Baker, Global Action on Men's Health (United Kingdom)

The case for global gender-neutral HPV vaccination ( Peter Baker, Global Action on Men's Health (United Kingdom) )

Boosting HPV vaccination in India: A call to action

Ms Sutapa Biswas - Cancer Foundation of India, Kolkata, India

Boosting HPV vaccination in India: A call to action ( Ms Sutapa Biswas - Cancer Foundation of India, Kolkata, India )

WCI's role in the prevention of tobacco related cancer among Beedi rolling women in India

Dr Surendran Veeraiah - Cancer Institute (WIA) Adyar, Chennai, India

WCI's role in the prevention of tobacco related cancer among Beedi rolling women in India ( Dr Surendran Veeraiah - Cancer Institute (WIA) Adyar, Chennai, India )

Alternative livelihood training programme for rural women who are employed in the tobacco industry in India

Ms Sheeba Paul - Exodus Exports Pvt Ltd, Chennai, India

Alternative livelihood training programme for rural women who are employed in the tobacco industry in India ( Ms Sheeba Paul - Exodus Exports Pvt Ltd, Chennai, India )

ESMO and WCLC: Latest developments in EGFR mutated NSCLC

Dr Matthew Krebs, Dr Antonio Passaro, Dr Enriqueta Felip and Prof Pascale Tomasini

ESMO and WCLC: Latest developments in EGFR mutated NSCLC ( Dr Matthew Krebs, Dr Antonio Passaro, Dr Enriqueta Felip and Prof Pascale Tomasini )

Predicting tumour mutations from pathology images may help increase personalised medicine utilisation

Dr Rom Leidner - Providence Cancer Institute, Portland, USA

Predicting tumour mutations from pathology images may help increase personalised medicine utilisation ( Dr Rom Leidner - Providence Cancer Institute, Portland, USA )

New NK-1 inhibitor HR20013 shows promising results in preventing chemotherapy-induced nausea and vomiting in NSCLC patients

Dr Li Zhang - Sun Yat-Sen University Cancer Centre, Guangzhou, China

New NK-1 inhibitor HR20013 shows promising results in preventing chemotherapy-induced nausea and vomiting in NSCLC patients ( Dr Li Zhang - Sun Yat-Sen University Cancer Centre, Guangzhou, China )

Tusamitamab ravtansine versus docetaxel in previously treated advanced nonsquamous NSCLC: Results from phase 3 CARMEN-LC03 trial

Prof Benjamin Besse - Gustave Roussy, Paris, France

Tusamitamab ravtansine versus docetaxel in previously treated advanced nonsquamous NSCLC: Results from phase 3 CARMEN-LC03 trial ( Prof Benjamin Besse - Gustave Roussy, Paris, France )

Cemiplimab monotherapy could be a new treatment option for first line advanced NSCLC patients

Dr Ana Baramidze - Todua Clinic, Tbilisi, Georgia

Cemiplimab monotherapy could be a new treatment option for first line advanced NSCLC patients ( Dr Ana Baramidze - Todua Clinic, Tbilisi, Georgia )

More from ecancer